Endobronchial thermoplasty for asthma

Felix Zamora1, Roy Cho1, Madhuri Rao2, Heidi Gibson3, H. Erhan Dincer1

1Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 2Division of Foregut and Thoracic Surgery, 3Cardiopulmonary Services, University of Minnesota, Minneapolis, MN, USA . Correspondence to: Felix Zamora, MD. Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, 420 Delaware St. SE, MMC 276, Minneapolis, MN 55455, USA. Email: This email address is being protected from spambots. You need JavaScript enabled to view it. .


Abstract: Asthma is an incurable chronic disease affecting approximately 24 million people in the United States. The hallmark features of asthma are reversible airflow obstruction, airway hyperresponsiveness, airway inflammation, bronchoconstriction, and excessive mucus secretion. Clinical symptoms include episodic or persistent breathlessness, wheezing, cough, or chest tightness/pressure. Forty-five percent of asthmatics continue to have yearly exacerbations and the disease is responsible for approximately 3,600 annual deaths. Pharmacologic advancements have continued to grow as the individual phenotypes of asthma are better delineated but there continues to be small population of asthmatics that are less responsive to pharmacologic therapy. Bronchial thermoplasty (BT) is an innovative procedure targeted primarily at decreasing airway smooth muscle (ASM) which is considered by some to be a vestigial organ. Decreasing the ASM bulk decreases hyperresponsiveness and bronchoconstriction leading to decreased exacerbations, decreased cost on the healthcare system, and improvement in patient quality of life.

PDF
HTML

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @worldallergy: WISC 2018 - Florence Dec. 6-9 Registration online will be closed on November 20th. After this date, registration will on…
17hreplyretweetfavorite
Interasma RT @worldallergy: Top 10 Scientific Articles in the field of psychosocial aspects of allergy published in 2017 (or 2016 as noted). https://…
17hreplyretweetfavorite
Interasma RT @Aller_MD: “#Asthma biologic prices ‘far out of alignment’ with benefit, says ICER” https://t.co/rIKq8LypH9 https://t.co/t8vGuROsUw
17hreplyretweetfavorite
Interasma RT @Aller_MD: “Risk Factors ID'd for Persistent Atopic Dermatitis in Kids Could help clinicians personalize disease prediction” https://t.c…
17hreplyretweetfavorite
Interasma RT @RhinologyO: “The otolaryngologists’ non-surgical training needs to extend beyond the limits of ENT” http…
18hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma